NCT05693129 - Pediatric Patients Aged 1 to 6 Years With APDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

April 9, 2025

Study Completion Date

February 28, 2026

Conditions

APDS

Interventions

DRUG

Leniolisib

The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).

Trial Locations (9)

National Institutes of Health, Bethesda

Hospital Universitario Virgen del Rocío, Seville

Rainbow Childrens Hospital, Shaker Heights

Texas Children's Hospital, Houston

University of California Los Angeles, Los Angeles

Kyoto University Hospital, Kyoto

Institute of Science Tokyo Hospital, Tokyo

Hospital Pediátrico de Coimbra da ULS Coimbra UNIDADE LOCAL DE SAÚDE DE COIMBRA, Coimbra

Great Ormond Street Hospital, London